A Novel 2-Carbon-Linked Dimeric Artemisinin With Potent Antileukemic Activity and Favorable Pharmacology.
AuthorKagan, Amanda B
Moses, Blake S
Mott, Bryan T
Anders, Nicole M
Rudek, Michelle A
Civin, Curt I
JournalFrontiers in Oncology
PublisherFrontiers Media S.A.
MetadataShow full item record
AbstractAcute myeloid leukemia (AML) remains a devastating disease, with low cure rates despite intensive standard chemotherapy regimens. In the past decade, targeted antileukemic drugs have emerged from research efforts. Nevertheless, targeted therapies are often effective for only a subset of patients whose leukemias harbor a distinct mutational or gene expression profile and provide only transient antileukemic responses as monotherapies. We previously presented single agent and combination preclinical data for a novel 3-carbon-linked artemisinin-derived dimer (3C-ART), diphenylphosphate analog 838 (ART838), that indicates a promising approach to treat AML, given its demonstrated synergy with targeted antileukemic drugs and large therapeutic window. We now report new data from our initial evaluation of a structurally distinct class of 2-carbon-linked dimeric artemisinin-derived analogs (2C-ARTs) with prior documented in vivo antimalarial activity. These 2C-ARTs have antileukemic activity at low (nM) concentrations, have similar cooperativity with other antineoplastic drugs and comparable physicochemical properties to ART838, and provide a viable path to clinical development.
Rights/TermsCopyright © 2022 Kagan, Moses, Mott, Rai, Anders, Rudek and Civin.
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/17933
- Antileukemic efficacy of a potent artemisinin combined with sorafenib and venetoclax.
- Authors: Moses BS, McCullough S, Fox JM, Mott BT, Bentzen SM, Kim M, Tyner JW, Lapidus RG, Emadi A, Rudek MA, Kingsbury TJ, Civin CI
- Issue date: 2021 Feb 9
- Artemisinin-derived dimer ART-838 potently inhibited human acute leukemias, persisted in vivo, and synergized with antileukemic drugs.
- Authors: Fox JM, Moynihan JR, Mott BT, Mazzone JR, Anders NM, Brown PA, Rudek MA, Liu JO, Arav-Boger R, Posner GH, Civin CI, Chen X
- Issue date: 2016 Feb 9
- Antileukemic activity and cellular effects of the antimalarial agent artesunate in acute myeloid leukemia.
- Authors: Kumar B, Kalvala A, Chu S, Rosen S, Forman SJ, Marcucci G, Chen CC, Pullarkat V
- Issue date: 2017 Aug
- Evaluation of artemisinins for the treatment of acute myeloid leukemia.
- Authors: Drenberg CD, Buaboonnam J, Orwick SJ, Hu S, Li L, Fan Y, Shelat AA, Guy RK, Rubnitz J, Baker SD
- Issue date: 2016 Jun
- Considerations on the mechanism of action of artemisinin antimalarials: part 1--the 'carbon radical' and 'heme' hypotheses.
- Authors: Haynes RK, Cheu KW, N'Da D, Coghi P, Monti D
- Issue date: 2013 Aug